Intravenous Iron Drugs Market Report 2025

The intravenous iron drugs market size has grown rapidly in recent years. It will grow from $3.44 billion in 2024 to $3.81 billion in 2025 at a compound annual growth rate (CAGR) of 10.6%. The growth in the historic period can be attributed to increasing prevalence of iron deficiency anemia, rising prevalence of chronic diseases, increasing healthcare spending, aging population, and rising incidence of target illnesses.

The intravenous iron drugs market size is expected to see rapid growth in the next few years. It will grow to $5.73 billion in 2029 at a compound annual growth rate (CAGR) of 10.8%. The growth in the forecast period can be attributed to government initiatives, research and development in the field of IV iron drugs, increasing demand for intravenous iron medicines, increasing number of research and development activities, and improvement in administration and formulation. Major trends in the forecast period include advanced intravenous iron therapies, advancements in drug development, shift towards more convenient iv iron therapies, strategic collaborations partnerships and acquisitions, and innovations in novel drug delivery systems.

The forecast of 10.8% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions are likely to burden nephrology and hematology centers by driving up costs of iron sucrose and ferric carboxymaltose formulations manufactured in India and Sweden, exacerbating anemia management expenses and increasing infusion therapy service burdens. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing incidence of chronic kidney disease (CKD) is expected to drive significant growth in the intravenous iron drugs market. CKD is a progressive condition characterized by the gradual decline of kidney function, impairing the body's ability to filter waste and excess fluids from the blood. This rising trend is largely attributed to the increasing prevalence of diabetes and hypertension two major contributors to kidney damage. Intravenous iron drugs play a crucial role in managing CKD-related anemia by restoring iron levels, improving hemoglobin concentrations, and enhancing oxygen delivery in the body. These benefits reduce reliance on erythropoiesis-stimulating agents and support better patient outcomes. For example, in June 2024, the Australian Institute of Health and Welfare reported that CKD-related mortality increased by 4.2% in 2021 and by 6.2% in 2022. In 2022 alone, CKD accounted for approximately 22,000 deaths in Australia, representing 11% of total fatalities. As a result, the growing burden of CKD is accelerating the demand for intravenous iron therapies.

Leading players in the intravenous iron drugs market are prioritizing the development of advanced intravenous (IV) iron replacement therapies to enhance safety, efficacy, and patient experiences. IV iron replacement therapy involves delivering iron directly into the bloodstream, making it an effective treatment for iron deficiency and anemia, particularly in patients who are unable to tolerate or absorb oral iron supplements. For instance, in June 2023, Daiichi Sankyo Company Limited a Japan-based pharmaceutical innovator announced that the U.S. Food and Drug Administration (FDA) had approved Injectafer (ferric carboxymaltose injection) for treating iron deficiency in adults with New York Heart Association class II/III heart failure. This approval supports the use of Injectafer to improve exercise capacity and addresses iron deficiency in a key patient population. Known for its rapid iron repletion capabilities, Injectafer offers a valuable alternative to oral therapies, enhancing treatment adherence and outcomes.

In August 2022, CSL Limited, an Australia-based biotechnology company known for its focus on plasma therapies and specialty pharmaceuticals, acquired Vifor Pharma for an undisclosed sum. This strategic acquisition enhances CSL’s capabilities in nephrology and iron deficiency management, significantly strengthening its portfolio in renal and cardiovascular care. Vifor Pharma AG, headquartered in Switzerland, is recognized globally for its expertise in iron deficiency treatments and nephrology-focused pharmaceuticals.

Major players in the intravenous iron drugs market are AbbVie Inc., Sanofi S.A., Amgen Inc., Fresenius SE & Co. KGaA, Teva Pharmaceutical Industries Ltd., CSL Limited, Sandoz Group AG., Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Galenica Ltd., Dr.Reddy's Laboratories, Hikma Pharmaceuticals plc, Zydus Lifesciences Limited, Biocon Limited, Kissei Pharmaceutical Co. Ltd., American Regent Inc., Akebia Therapeutics Inc., Rockwell Medical Inc., Pharmacosmos A/S, Shield Therapeutics plc, Mitsubishi Tanabe Pharma Corporation.

North America was the largest region in the intravenous iron drugs market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in intravenous iron drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the intravenous iron drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The intravenous iron drugs market consists of sales of ferric gluconate, ferumoxytol, ferric derisomaltose, and sodium ferric gluconate. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The intravenous iron drugs market research report is one of a series of new reports that provides intravenous iron drugs market statistics, including the intravenous iron drugs global market size, regional shares, competitors with the intravenous iron drugs market share, detailed intravenous iron drugs market segments, market trends, and opportunities, and any further data you may need to thrive in the intravenous iron drugs. This intravenous iron drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

Intravenous iron drugs are iron formulations administered directly into the bloodstream to treat iron deficiency and iron deficiency anemia, particularly in patients who cannot tolerate or do not respond well to oral iron supplements. These drugs quickly elevate iron levels, support hemoglobin production, and enhance oxygen transport in the body, helping to relieve symptoms such as fatigue and weakness.

The primary product types of intravenous iron drugs include iron dextran, iron sucrose, ferric carboxymaltose, and other formulations. Iron dextran is an injectable iron therapy used for rapid iron replenishment in patients with severe deficiencies where oral iron is ineffective or poorly tolerated. These drugs are used to treat various conditions, including chronic kidney disease, inflammatory bowel disease, cancer, and other disorders. They are distributed through hospital pharmacies, retail pharmacies, and online pharmacies.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.